GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (NAS:GILD) » Definitions » PS Ratio

Gilead Sciences (Gilead Sciences) PS Ratio

: 3.09 (As of Today)
View and export this data going back to 1992. Start your Free Trial

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Gilead Sciences's share price is $66.72. Gilead Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $21.56. Hence, Gilead Sciences's PS Ratio for today is 3.09.

Good Sign:

Gilead Sciences Inc stock PS Ratio (=3.07) is close to 1-year low of 3.07

The historical rank and industry rank for Gilead Sciences's PS Ratio or its related term are showing as below:

GILD' s PS Ratio Range Over the Past 10 Years
Min: 2.68   Med: 3.81   Max: 12.5
Current: 3.08

During the past 13 years, Gilead Sciences's highest PS Ratio was 12.50. The lowest was 2.68. And the median was 3.81.

GILD's PS Ratio is ranked worse than
65.77% of 1005 companies
in the Drug Manufacturers industry
Industry Median: 2.16 vs GILD: 3.08

Gilead Sciences's Revenue per Sharefor the three months ended in Dec. 2023 was $5.67. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $21.56.

Warning Sign:

Gilead Sciences Inc revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Gilead Sciences was -0.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 3.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was 5.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was 6.60% per year.

During the past 13 years, Gilead Sciences's highest 3-Year average Revenue per Share Growth Rate was 162.80% per year. The lowest was -7.70% per year. And the median was 31.60% per year.

Back to Basics: PS Ratio


Gilead Sciences PS Ratio Historical Data

The historical data trend for Gilead Sciences's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.70 2.98 3.36 3.97 3.76

Gilead Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.97 3.87 3.55 3.45 3.76

Competitive Comparison

For the Drug Manufacturers - General subindustry, Gilead Sciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences PS Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's PS Ratio distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's PS Ratio falls into.



Gilead Sciences PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Gilead Sciences's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=66.72/21.561
=3.09

Gilead Sciences's Share Price of today is $66.72.
Gilead Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $21.56.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Gilead Sciences  (NAS:GILD) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Gilead Sciences PS Ratio Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences (Gilead Sciences) Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Executives
Andrew D Dickinson officer: EVP, Chief Financial Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Johanna Mercier officer: Chief Commercial Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Merdad Parsey officer: Chief Medical Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Patterson officer: SVP, Controllership 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Diane E. Wilfong officer: SVP, Controller & CAO 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Deborah H Telman officer: EVP, Corporate Affairs & GC 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Brett A Pletcher officer: EVP, Gen Counsel & Corp Sec 333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Jeffrey Bluestone director C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858
Anthony Welters director
Javier Rodriguez director 601 HAWAII ST., EL SEGUNDO CA 90245
John Francis Cogan director 2010 NORTH FIRST STREET, SUITE 310, SAN JOSE CA 95131
Gayle E Wilson director C/O GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Olsen Per Wold director C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Horning director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Richard James Whitley director UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711